Efficacy and Safety of S-1 Plus Oxaliplatin in First-line Treatment of Ederly Patients With Advanced Gastric Cancer

Phase 2 Unknown 60 enrolled Aiping Zhou

NaSingle-groupOpen-labelTreatment

Summary

Elderly patients have poor tolerance and physical condition, we will prove 2-week schedule of oxaliplatin plus S-1 have a good efficacy and a better safety for elderly patients with advanced or recurrent gastric cancer.

Timeline

Start: 2016-05-11
Primary completion: 2021-12-01
Completion: 2022-12-01

Publications

Jiang Z, Zhou A, Sun Y, Zhang W. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study. BMC Cancer. 2022 Mar 9;22(1):253. doi: 10.1186/s12885-022-09332-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Oxaliplatin	Small molecule	85 mg/m2	Intravenous
Subject	S-1	Small molecule	40 mg	—
Subject	S-1	Small molecule	50 mg	—
Subject	S-1	Small molecule	60 mg	—

Indications

No indication recorded.